The first cancer vaccine, known as Provenge ... are being developed by other companies around the world. But with their stock skyrocketing following the announcement, right now, Dendreon has much to celebrate.
Canada's Valeant Pharmaceuticals International Inc. said its affiliate will sell its Dendreon cancer business to China's Sanpower Group Co. Ltd. for $819.9 million, as the drugmaker continues to shed its non-core assets to repay debt. …
SEATTLE--(BUSINESS WIRE)--Dendreon Corporation (Nasdaq:DNDN) today reported results for the third quarter ended September 30, 2013. Net product revenue for the quarter was $68 million compared to $77.9 million for the quarter …
NEW YORK (Reuters) – An experimental medicine from Dendreon Corp improved survival in men with advanced forms of prostate cancer, the company said on Tuesday, bolstering chances of it becoming the first approved therapeutic …
Dendreon may be on its last legs, but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences, seeding about $1.3 million into the company …
Seattle-based Dendreon Corp. has cut 34 employees and reassigned senior executives in a push to get its experimental treatment for advanced prostate cancer to market, the biotechnology company announced Friday. If approved by the …
Beleaguered Valeant Pharmaceuticals International, Inc. VRX announced that its affiliate has entered into a definitive agreement to sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower …
SEATTLE--(BUSINESS WIRE)--Dendreon Corporation (Nasdaq: DNDN) today reported results for the fourth quarter and full year ended December 31, 2012. Net product revenue for the year ended December 31, 2012 was $325.3 million …
Dendreon may be on its last legs, but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences, seeding about $1.3 million into the company …
Beleaguered Valeant Pharmaceuticals International, Inc. VRX announced that its affiliate has entered into a definitive agreement to sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower …